siRNA-mediated inhibition of antiapoptotic genes enhances chemotherapy efficacy in bladder cancer cells

Anticancer Research

Volumn 32, Issue 10, 2012, Pages 4313-4318

  Kunze, Doreen ^a   Kati, Erdmann ^a   Froehner, Michael ^a   Wirth, Manfred P ^a   Fuessel, Susanne ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Apoptosis; Bladder cancer; Combination therapy; Resistance to chemotherapy; RNA interference; siRNA

Indexed keywords

CISPLATIN; MITOMYCIN C; PROTEIN BCL 2; PROTEIN BCL XL; SMALL INTERFERING RNA; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL VIABILITY; DRUG EFFECT; DRUG RESPONSE; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; CISPLATIN; GENE SILENCING; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MITOMYCIN; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; URINARY BLADDER NEOPLASMS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84867771844     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781, 2010.
2. Ploeg M, Aben KK and Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol 27: 289-293, 2009.
3. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J and Roupret M: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59: 997-1008, 2011.
4. Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van de Beek C, Gorlia T and de Reijke TM: Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57: 766-773, 2010.
5. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A and Witjes JA: Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59: 1009-1018, 2011.
6. Dogliotti L, Carteni G, Siena S, Bertetto O, Martoni A, Bono A, Amadori D, Onat H and Marini L: Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 52: 134-141, 2007. (Pubitemid 46803003)
7. Gimenez-Bonafe P, Tortosa A and Perez-Tomas R: Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets 9: 320-340, 2009.
8. Brunelle JK and Letai A: Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 122: 437-441, 2009.
9. Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, Salvesen GS, Reed JC and Altieri DC: An IAP-IAP complex inhibits apoptosis. J Biol Chem 279: 34087-34090, 2004. (Pubitemid 39318028)
10. Eckelman BP, Salvesen GS and Scott FL: Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 7: 988-994, 2006. (Pubitemid 44480512)
11. Cooke PW, James ND, Ganesan R, Burton A, Young LS and Wallace DM: Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU Int 85: 829-835, 2000. (Pubitemid 30242786)
12. Hausladen DA, Wheeler MA, Altieri DC, Colberg JW and Weiss RM: Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome. J Urol 170: 230-234, 2003. (Pubitemid 36734468)
13. Weiss C, von Romer F, Capalbo G, Ott OJ, Wittlinger M, Krause SF, Sauer R, Rodel C and Rodel F: Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys 74: 1455-1460, 2009.
14. Cho HJ, Kim JK, Kim KD, Yoon HK, Cho MY, Park YP, Jeon JH, Lee ES, Byun SS, Lim HM, Song EY, Lim JS, Yoon DY, Lee HG and Choe YK: Up-regulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett 237: 56-66, 2006.
15. Lebedeva I, Raffo A, Rando R, Ojwang J, Cossum P and Stein CA: Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides. J Urol 166: 461-469, 2001. (Pubitemid 32652224)
16. Bilim V, Kasahara T, Hara N, Takahashi K and Tomita Y: Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int J Cancer 103: 29-37, 2003. (Pubitemid 35424202)
17. Fuessel S, Herrmann J, Ning S, Kotzsch M, Kraemer K, Schmidt U, Hakenberg OW, Wirth MP and Meye A: Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA. Cancer Lett 232: 243-254, 2006. (Pubitemid 43170974)
18. Han Z, Chatterjee D, Early J, Pantazis P, Hendrickson EA and Wyche JH: Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL. Cancer Res 56: 1621-1628, 1996.
19. Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu K and Takei Y: Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int J Cancer 125: 2978-2990, 2009.
20. Okamoto K, Ocker M, Neureiter D, Dietze O, Zopf S, Hahn EG and Herold C: bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells. J Cell Mol Med 11: 349-361, 2007. (Pubitemid 46693333)
21. Yang H, Fu JH, Hu Y, Huang WZ, Zheng B, Wang G, Zhang X and Wen J: Influence of SiRNA targeting survivin on chemosensitivity of H460/cDDP lung cancer cells. J Int Med Res 36: 734-747, 2008.
22. Zhang S, Ding F, Luo A, Chen A, Yu Z, Ren S, Liu Z and Zhang L: XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. Cancer Biol Ther 6: 973-980, 2007.
23. Kunze D, Kraemer K, Erdmann K, Froehner M, Wirth MP and Fuessel S: Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells. Int J Oncol 2012. Doi: 10.3892/ijo.2012.1549.
24. Kunze D, Wuttig D, Fuessel S, Kraemer K, Kotzsch M, Meye A, Grimm MO, Hakenberg OW and Wirth MP: Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells. Anticancer Res 28: 2259-2263, 2008.
25. Yang D, Song X, Zhang J, Ye L, Wang S, Che X, Wang J, Zhang Z, Wang L and Shi W: Therapeutic potential of siRNA-mediated combined knockdown of the IAP genes (Livin, XIAP, and Survivin) on human bladder cancer T24 cells. Acta Biochim Biophys Sin (Shanghai) 42: 137-144, 2010.
26. Duggan BJ, Maxwell P, Kelly JD, Canning P, Anderson NH, Keane PF, Johnston SR and Williamson KE: The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma. J Urol 166: 1098-1105, 2001. (Pubitemid 32751052)
27. Warmann SW, Frank H, Heitmann H, Ruck P, Herberts T, Seitz G and Fuchs J: Bcl-2 gene silencing in pediatric epithelial liver tumors. J Surg Res 144: 43-48, 2008. (Pubitemid 350234956)